Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: belhabri a. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E. Belhabri A, et al. Hematol J. 2002;3(1):49-55. doi: 10.1038/sj.thj.6200141. Hematol J. 2002. PMID: 11960396 Clinical Trial.
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, Vargaftig J, Uzunov M, Belhabri A, Bertoli S, Cotteret S, Vergé V, Renneville A, Rosselli F, Antony-Debre I, Rouleau E, Salviat F, Caron O, Delaloge S, Pautier P, Etienne G, Recher C, Vey N, De Botton S, Leary A, Marzac C, Micol JB. Martin JE, et al. Among authors: belhabri a. Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6. Ann Oncol. 2021. PMID: 34107346 Free article. No abstract available.
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Laloi L, Billotey NC, Dumas PY, Paul F, Villate A, Simand C, Fornecker L, Puisset F, Bertoli S, Simonet MB, Laribi K, Houyou D, Santagostino A, Michel C, Guepin GR, Guerineau E, Tabrizi R, Hunault M, Giltat A, Kaphan E, Bulabois C, Cartet E, Rocher C, Lachenal F, Morisset S, Récher C, Pigneux A, Belhabri A, Michallet M, Michallet AS. Laloi L, et al. Among authors: belhabri a. Cancer Med. 2023 Mar;12(6):7175-7181. doi: 10.1002/cam4.5459. Epub 2022 Dec 8. Cancer Med. 2023. PMID: 36482507 Free PMC article.
Clinical outcome of therapy-related acute myeloid leukemia patients. Real-life experience in a University Hospital and a Cancer Center in France.
Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, Hayette S, Tigaud I, Plesa A, Labussiere-Wallet H, Sobh M, Michallet AS, Marie B, Nicolini FE, Guillermin Y, Gaëlle F, Lebras L, Rey P, Jauffret-Bertholon L, Laude MC, Sandrine L, Michallet M. Belhabri A, et al. Cancer Med. 2023 Aug;12(16):16929-16944. doi: 10.1002/cam4.6322. Epub 2023 Aug 7. Cancer Med. 2023. PMID: 37548369 Free PMC article.
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Chalandon Y, Rousselot P, Chevret S, Cayuela JM, Kim R, Huguet F, Chevallier P, Graux C, Thiebaut-Bertrand A, Chantepie S, Thomas X, Vincent L, Berthon C, Hicheri Y, Raffoux E, Escoffre-Barbe M, Plantier I, Joris M, Turlure P, Pasquier F, Belhabri A, Guepin GR, Blum S, Gregor M, Lafage-Pochitaloff M, Quessada J, Lhéritier V, Clappier E, Boissel N, Dombret H. Chalandon Y, et al. Among authors: belhabri a. Blood. 2024 Jun 6;143(23):2363-2372. doi: 10.1182/blood.2023023502. Blood. 2024. PMID: 38452207 Clinical Trial.
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Garciaz S, et al. Among authors: belhabri a. Am J Hematol. 2024 Oct;99(10):1870-1876. doi: 10.1002/ajh.27417. Epub 2024 Jun 20. Am J Hematol. 2024. PMID: 38899566
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, Hicheri Y, Wartiovaara-Kautto U, Raffoux E, Cluzeau T, Balsat M, Roth-Guepin G, Tavernier E, Lepretre S, Bilger K, Bergugnat H, Berceanu A, Alexis M, Doubek M, Brissot E, Hunault-Berger M, Lebon D, Turlure P, Chantepie S, Belhabri A, Wickenhauser S, Bastie JN, Cacheux V, Himberlin C, Banos A, Gardin C, Bonnet S, Plantier I, Pica GM, Escoffre-Barbe M, Boissel N, Dombret H, Clappier E, Rousselot P; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) and the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL). Chevallier P, et al. Among authors: belhabri a. J Clin Oncol. 2024 Oct 17:JCO2400490. doi: 10.1200/JCO.24.00490. Online ahead of print. J Clin Oncol. 2024. PMID: 39418626
47 results